Your browser is no longer supported. Please, upgrade your browser.
Settings
ARQT [NASD]
Arcutis Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-3.90 Insider Own4.10% Shs Outstand43.03M Perf Week3.38%
Market Cap1.44B Forward P/E- EPS next Y-5.04 Insider Trans-4.32% Shs Float27.19M Perf Month-14.90%
Income-135.70M PEG- EPS next Q-0.86 Inst Own82.20% Short Float6.84% Perf Quarter-3.40%
Sales- P/S- EPS this Y-231.80% Inst Trans17.48% Short Ratio6.94 Perf Half Y13.81%
Book/sh6.29 P/B4.38 EPS next Y-15.90% ROA-55.20% Target Price- Perf Year3.42%
Cash/sh5.45 P/C5.05 EPS next 5Y9.80% ROE-60.70% 52W Range17.51 - 39.85 Perf YTD-2.17%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.95% Beta-
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin- 52W Low57.17% ATR1.77
Employees54 Current Ratio13.00 Sales Q/Q- Oper. Margin- RSI (14)42.88 Volatility5.21% 6.61%
OptionableYes Debt/Eq0.00 EPS Q/Q-130.60% Profit Margin- Rel Volume0.55 Prev Close28.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume267.75K Price27.52
Recom1.80 SMA20-3.25% SMA50-13.37% SMA2000.22% Volume147,660 Change-4.04%
Nov-09-20Upgrade Goldman Neutral → Buy $34 → $36
Oct-08-20Initiated Truist Buy $38
Feb-25-20Initiated Guggenheim Buy $36
Feb-25-20Initiated Goldman Neutral $30
Feb-25-20Initiated Cowen Outperform $55
Feb-25-20Initiated Cantor Fitzgerald Overweight $50
Apr-12-21 09:05AM  
Mar-26-21 09:00AM  
Mar-18-21 09:05AM  
Mar-17-21 04:05PM  
Feb-25-21 05:15PM  
Feb-18-21 09:00AM  
Feb-16-21 04:05PM  
09:00AM  
Feb-06-21 01:14AM  
Feb-03-21 12:00PM  
Feb-02-21 08:03PM  
Feb-01-21 04:09PM  
07:30AM  
Jan-20-21 09:00AM  
Jan-13-21 09:00AM  
Jan-11-21 09:00AM  
Dec-21-20 09:27AM  
Dec-10-20 11:05PM  
Dec-09-20 09:00AM  
Dec-07-20 09:00AM  
Dec-02-20 04:05PM  
Dec-01-20 04:05PM  
Nov-27-20 11:55AM  
Nov-23-20 07:30AM  
Nov-11-20 04:05PM  
Nov-05-20 04:05PM  
Nov-04-20 04:05PM  
Nov-02-20 09:00AM  
Oct-29-20 09:07PM  
Oct-26-20 09:00AM  
Oct-08-20 10:00AM  
Oct-06-20 04:05PM  
Oct-02-20 12:40PM  
Oct-01-20 10:47PM  
Sep-29-20 04:51PM  
02:36PM  
08:00AM  
Sep-16-20 09:00AM  
Sep-15-20 09:00AM  
Sep-08-20 09:00AM  
Aug-11-20 04:02PM  
Aug-10-20 09:00AM  
Aug-04-20 09:00AM  
Aug-03-20 09:00AM  
Jul-31-20 09:00AM  
Jul-27-20 09:00AM  
Jul-20-20 09:00AM  
Jul-15-20 05:07PM  
Jul-13-20 09:00AM  
Jun-22-20 11:47AM  
09:00AM  
Jun-10-20 04:05PM  
Jun-01-20 09:00AM  
May-27-20 09:00AM  
May-12-20 04:05PM  
Apr-27-20 08:30AM  
Apr-21-20 09:00AM  
Mar-23-20 08:30AM  
Mar-16-20 08:37AM  
Mar-05-20 08:30AM  
Mar-03-20 08:30AM  
Feb-19-20 08:30AM  
Feb-14-20 08:00PM  
Feb-13-20 08:30AM  
Feb-04-20 04:05PM  
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Watanabe Todd FranklinPresident and CEOApr 05Sale29.931,75052,378595,416Apr 06 05:30 PM
Welgus Howard G.DirectorApr 01Option Exercise3.952,2008,679210,486Apr 05 05:33 PM
Welgus Howard G.DirectorApr 01Sale29.492,20064,880208,286Apr 05 05:33 PM
CHAUDHURI BHASKARDirectorMar 22Sale31.1010,000311,021871,391Mar 24 11:33 AM
Welgus Howard G.DirectorMar 16Option Exercise1.172,6533,114208,286Mar 18 01:59 PM
Smither John WChief Financial OfficerMar 10Option Exercise1.6850084046,821Mar 11 03:59 PM
Smither John WChief Financial OfficerMar 10Sale32.901,25041,12586,715Mar 11 03:59 PM
Smither John WChief Financial OfficerMar 10Sale32.9050016,45046,321Mar 11 03:59 PM
Watanabe Todd FranklinPresident and CEOMar 05Sale30.551,75053,462597,166Mar 05 03:56 PM
Smither John WChief Financial OfficerMar 04Option Exercise1.6812,39620,83346,321Mar 05 03:55 PM
Watanabe Todd FranklinPresident and CEOMar 02Sale35.192,10774,136566,216Mar 03 04:51 PM
Welgus Howard G.DirectorMar 01Option Exercise3.922,2008,626207,833Mar 03 04:45 PM
OSBORNE DAVID WChief Technical OfficerMar 01Sale34.5778026,968237,253Mar 03 04:50 PM
Turney Patricia A.SVP, OperationsMar 01Sale34.5293432,2429,271Mar 03 04:49 PM
Lock Kenneth A.Chief Commercial OfficerMar 01Sale34.2093331,90822,167Mar 03 04:47 PM
Smither John WChief Financial OfficerMar 01Sale34.2077326,44024,425Mar 03 04:48 PM
Welgus Howard G.DirectorMar 01Sale34.372,20075,610205,633Mar 03 04:45 PM
CHAUDHURI BHASKARDirectorFeb 22Sale35.5210,000355,191881,391Feb 24 03:33 PM
Welgus Howard G.DirectorFeb 16Option Exercise1.172,6543,116205,633Feb 17 08:35 PM
Smither John WChief Financial OfficerFeb 10Option Exercise1.687501,26025,948Feb 12 05:32 PM
Smither John WChief Financial OfficerFeb 10Sale35.642,00071,28087,965Feb 12 05:32 PM
Smither John WChief Financial OfficerFeb 10Sale35.6475026,73025,198Feb 12 05:32 PM
Watanabe Todd FranklinPresident and CEOFeb 05Option Exercise1.6810,00016,806578,323Feb 08 04:00 PM
Watanabe Todd FranklinPresident and CEOFeb 05Sale34.2910,000342,916568,323Feb 08 04:00 PM
Welgus Howard G.DirectorFeb 04Option Exercise1.6819,86133,378202,979Feb 08 01:45 PM
Smither John WChief Financial OfficerFeb 01Option Exercise1.681,2502,10126,448Feb 03 11:23 AM
Welgus Howard G.DirectorFeb 01Option Exercise1.682,2003,697185,318Feb 03 11:24 AM
Welgus Howard G.DirectorFeb 01Sale34.352,20075,572183,118Feb 03 11:24 AM
Smither John WChief Financial OfficerFeb 01Sale35.003,750131,25089,965Feb 03 11:23 AM
Smither John WChief Financial OfficerFeb 01Sale35.001,25043,75025,198Feb 03 11:23 AM
CHAUDHURI BHASKARDirectorFeb 01Sale33.259,949330,804891,391Feb 02 07:39 PM
CHAUDHURI BHASKARDirectorJan 29Sale27.50511,402901,340Feb 02 07:39 PM
Smither John WChief Financial OfficerJan 19Option Exercise1.6850084025,698Jan 21 04:41 PM
Smither John WChief Financial OfficerJan 19Sale30.001,25037,50093,715Jan 21 04:41 PM
Smither John WChief Financial OfficerJan 19Sale30.0050015,00025,198Jan 21 04:41 PM
Welgus Howard G.DirectorJan 12Option Exercise0.581,222709183,118Jan 14 11:11 AM
Welgus Howard G.DirectorJan 04Option Exercise1.682,2003,697184,096Jan 06 01:16 PM
Welgus Howard G.DirectorJan 04Sale27.822,20061,215181,896Jan 06 01:16 PM
Welgus Howard G.DirectorDec 14Option Exercise0.581,222709181,896Dec 16 03:14 PM
Smither John WChief Financial OfficerDec 14Option Exercise1.681,5002,52126,698Dec 16 03:14 PM
OSBORNE DAVID WChief Technical OfficerDec 14Sale30.0015,000450,000250,533Dec 16 03:15 PM
Smither John WChief Financial OfficerDec 14Sale30.003,750112,50094,965Dec 16 03:14 PM
Smither John WChief Financial OfficerDec 14Sale30.001,50045,00025,198Dec 16 03:14 PM
Welgus Howard G.DirectorDec 01Option Exercise1.682,2003,696182,044Dec 03 07:40 PM
Welgus Howard G.DirectorDec 01Sale25.982,20057,155179,844Dec 03 07:40 PM
Welgus Howard G.DirectorNov 12Option Exercise0.581,222709179,844Nov 13 11:57 AM
Welgus Howard G.DirectorNov 02Option Exercise1.682,2003,696180,822Nov 04 04:33 PM
Welgus Howard G.DirectorNov 02Sale18.272,20040,186178,622Nov 04 04:33 PM
Lock Kenneth A.Chief Commercial OfficerOct 26Option Exercise6.522,66817,39521,863Oct 27 02:03 PM
Lock Kenneth A.Chief Commercial OfficerOct 22Option Exercise6.522,69517,57119,195Oct 23 01:27 PM
Lock Kenneth A.Chief Commercial OfficerOct 15Option Exercise6.527,50048,90016,500Oct 16 02:06 PM
Welgus Howard G.DirectorOct 15Option Exercise0.581,222709178,622Oct 16 02:06 PM
ORBIMED ADVISORS LLCDirectorOct 02Buy25.00496,00012,400,0004,267,564Oct 06 05:27 PM
SILVERSTEIN JONATHANDirectorOct 02Buy25.00496,00012,400,0004,267,564Oct 06 05:23 PM
Welgus Howard G.DirectorOct 01Option Exercise1.682,2003,696179,210Oct 05 09:13 PM
Welgus Howard G.DirectorOct 01Sale27.652,20060,829177,400Oct 05 09:13 PM
Watanabe Todd FranklinPresident and CEOSep 29Option Exercise1.683,0005,042569,928Oct 01 09:02 PM
Watanabe Todd FranklinPresident and CEOSep 29Option Exercise1.683,0005,042569,928Jan 07 02:39 PM
Smither John WChief Financial OfficerSep 29Option Exercise1.6850084024,375Oct 01 09:00 PM
OSBORNE DAVID WChief Technical OfficerSep 29Sale30.0015,000450,000264,279Oct 01 09:01 PM
Watanabe Todd FranklinPresident and CEOSep 29Sale30.003,00090,000566,928Jan 07 02:39 PM
Watanabe Todd FranklinPresident and CEOSep 29Sale30.003,00090,000566,928Oct 01 09:02 PM
Smither John WChief Financial OfficerSep 29Sale30.001,25037,50098,715Oct 01 09:00 PM
Smither John WChief Financial OfficerSep 29Sale30.0050015,00023,875Oct 01 09:00 PM
Welgus Howard G.DirectorSep 15Option Exercise0.581,222709177,400Sep 16 05:57 PM
Welgus Howard G.DirectorSep 01Option Exercise1.682,2003,696178,378Sep 02 11:48 AM
Welgus Howard G.DirectorSep 01Sale24.382,20053,643176,178Sep 02 11:48 AM
Welgus Howard G.DirectorAug 20Option Exercise1.685,0008,400176,178Aug 21 02:19 PM
Welgus Howard G.DirectorAug 18Option Exercise1.685,0768,528171,178Aug 19 05:48 PM
Welgus Howard G.DirectorAug 14Option Exercise0.586,1103,545166,102Aug 18 04:12 PM
Welgus Howard G.DirectorAug 03Option Exercise1.682,8004,704162,725Aug 05 05:11 PM
Welgus Howard G.DirectorAug 03Sale25.632,80071,764159,992Aug 05 05:11 PM
Smither John WChief Financial OfficerJun 11Option Exercise1.6814,87524,999123,840Jun 15 03:15 PM